Comparison
Semaglutid vs. Tirzepatide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Metabolic
CAS no.
910463-68-2
2023788-19-2
Molecular weight
4113.6 g/mol
4813 g/mol
Half-life
165 h
116 h
Sequence
modifiziertes GLP-1-Analogon (31 AS) mit C18-Fettsäure-LinkerYXEGTFTSDYSIYLDKIAQKAFVQWLIAGGPSSGAPPPSMechanism of action
Semaglutid
Long-acting agonist at the GLP-1 receptor. Structurally a modified glucagon-like peptide 1 whose long half-life is achieved via a fatty-acid side chain and reversible albumin binding. Acts centrally on satiety and peripherally on glucose-dependent insulin secretion and delayed gastric emptying.
Tirzepatide
Tirzepatide is a 39-amino-acid peptide acting as a dual agonist at the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. Activation of both incretin receptors via G-protein-coupled signalling raises insulin secretion in a glucose-dependent manner, lowers glucagon secretion and delays gastric emptying. Centrally, satiety perception is modulated. A fatty-acid side chain binds to serum albumin and extends the half-life to about five days.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
4
4
of which in humans
3
4
Effects recorded
3
4
Open conflicts
1
1
Documented adverse events
5
2
Legal status
Full entries
Frequently asked questions
- What is the difference between Semaglutid and Tirzepatide?
- Semaglutid is classified as "Metabolic", while Tirzepatide is classified as "Metabolic". Semaglutid: Long-acting GLP-1 receptor agonist. Approved as a medicinal product for type-2 diabetes (Ozempic, Rybelsus), chronic weight management (Wegovy) and cardiovascular risk in obesity. One of the best-studied substances on this platform — many large human RCTs. Tirzepatide: Synthetic peptide that simultaneously activates the GLP-1 and GIP receptor (dual agonist). Approved in the US and EU for type 2 diabetes (Mounjaro) and obesity (Zepbound). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Semaglutid or Tirzepatide?
- The highest available evidence level is "Human RCT" for Semaglutid and "Human RCT" for Tirzepatide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Semaglutid and Tirzepatide in Germany and the United States?
- Germany: Semaglutid — Prescription, Tirzepatide — Prescription. United States: Semaglutid — Prescription, Tirzepatide — Prescription. These are factual summaries with source and review date on the individual pages.